Andreas Saltos, MD

Cancer Focus:
Lung Cancer, Mesothelioma, Pancoast Tumor, Thymoma

Dr. Andreas Saltos is a Medical Oncologist and the Clinical Research Medical Director in the Department of Thoracic Oncology at Moffitt Cancer Center. Dr. Saltos earned his MD from the University of Maryland School of Medicine in Baltimore. He completed his Internal Medicine Residency at the University of Maryland Medical Center in Baltimore before moving to Tampa, where he completed a Hematology and Medical Oncology Fellowship at the University of South Florida Morsani College of Medicine and Moffitt Cancer Center.

Dr. Saltos specializes in the treatment of thoracic malignancies, including all forms and stages of lung cancer.  In his clinical practice he strives to match patients with the optimal treatments that are tailored to their specific cancer and individual needs.  The ability to work with an incredible cancer team and apply the latest advances to treat patients in the clinic is what makes him excited to work at Moffitt. He also dedicates a significant portion of his effort to research.  His focus is in clinical research aiming to find better treatments for lung cancers, including using new strategies for targeted therapy and immunotherapy.  He is currently leading and developing clinical trials investigating novel drugs or treatment combinations which either target the specific genetic features of lung cancers or recruit the immune system to combat cancer. 

 

Education & Training

Board Certification:

• Medical Oncology -

Fellowship:

• University of South Florida Moffitt Cancer Center - Hematology and Medical Oncology

Residency:

• University of Maryland Medical Center - Internal Medicine

Medical School:

• University of Maryland School of Medicine - MD

Clinical Trial 20530
NAUTIKA1: A MULTICENTER, PHASE II, NEOADJUVANT AND ADJUVANT STUDY OF MULTIPLE THERAPIES IN BIOMARKER-SELECTED PATIENTS WITH RESECTABLE STAGES IB-III NON-SMALL CELL LUNG CANCER
Condition: Thoracic
Status: Open

Clinical Trial 21399
Phase I Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention: BMS-936558 (Nivolumab); MEM-288 (); Nivolumab (Opdivo); Pembrolizumab (Keytruda); Taxotere (docetaxel); docetaxel ()
Status: Open

Clinical Trial 21586
LEADER Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in EaRly Stage Lung Cancer
Condition: Thoracic
Status: Open

Clinical Trial 23094
A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 antibody) in Combination with Cemiplimab (Anti-PD-1 antibody) versus Cemiplimab Monotherapy in First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with Tumors Expressing PD-L1 >=50%
Condition: Thoracic
Intervention: Cemiplimab (); Fianlimab (); Placebo (); REGN2810 (Cemiplimab)
Status: OPEN (SUSPENDED)

Clinical Trial 23549
A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination with Atezolizumab in Patients with Advanced Solid Tumors
Condition: Thoracic
Intervention: Atezolizumab (Tecentriq); VET3-TGI ()
Status: Open

Clinical Trial 23576
A Phase II/III, multisite, randomized master protocol for a global trial of BNT327 in combination with chemotherapy and other investigational agents in first-line non-small cell lung cancer
Condition: Thoracic
Intervention: Alimta (Pemetrexed); BNT327 (); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxol (paclitaxel); carboplatin (); paclitaxel ()
Status: OPEN (SUSPENDED)

Clinical Trial 23583
Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
Condition: Thoracic
Intervention: N-803 (); Taxotere (docetaxel); Tislelizumab (); docetaxel ()
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Gonzalez BD, Li X, Gudenkauf LM, Pullukkara JJ, Oswald LB, Hoogland AI, Le T, El Naqa I, Saltos AN, Haura EB, Luo Y. Using Bayesian Networks to Predict Urgent Care Visits in Patients Receiving Systemic Therapy for Non-Small Cell Lung Cancer. JCO Clin Cancer Inform. 2025 Sep.9:e2400315. Pubmedid: 40939115. Pmcid: PMC12483286.
• Le X, Hernandez M, Heeke S, Saltos A, Heymach JV. Reply to: Osimertinib Plus Antiangiogenic Agents: A Promising New Paradigm With Uncertain Results. J Clin Oncol. 2025 May.43(13):1613-1614. Pubmedid: 39993244.
• Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbó F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Leighl NB, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Jänne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. N ...
• Le X, Patel JD, Shum E, Baik C, Sanborn RE, Shu CA, Kim C, Fidler MJ, Hall R, Elamin YY, Tu J, Blumenschein G, Zhang J, Gibbons D, Gay C, Mohindra NA, Chae Y, Boumber Y, Sabari J, Santana-Davila R, Rogosin S, Herzberg B, Creelan B, Pellini B, Tanvetyanon T, Heeke S, Hernandez M, Gray JE, Saltos A, Heymach JV. A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial). J Clin Oncol. 2025 Feb.43(4):403-411. Pubmedid: 39378386. Pmcid: PMC11776886.
• Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbó F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Lieghl N, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Jänne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Nov.635( ...
• Alontaga AY, Cano P, Ozakinci H, Puskas JA, Stewart PA, Welsh EA, Yoder SJ, Hicks JK, Saltos AN, Bossler AD, Haura EB, Koomen JM, Boyle TA. Implementation of a High-Accuracy Targeted Gene Expression Panel for Clinical Care. J Mol Diagn. 2024 Aug.26(8):685-699. Pubmedid: 38777037. Pmcid: PMC11299514.
• Smit EF, Felip E, Uprety D, Nagasaka M, Nakagawa K, Paz-Ares Rodríguez L, Pacheco JM, Li BT, Planchard D, Baik C, Goto Y, Murakami H, Saltos A, Pereira K, Taguchi A, Cheng Y, Yan Q, Feng W, Tsuchihashi Z, Jänne PA. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial. Lancet Oncol. 2024 Apr.25(4):439-454. Pubmedid: 38547891.
• Saltos AN, Creelan BC, Tanvetyanon T, Chiappori AA, Antonia SJ, Shafique MR, Ugrenovic-Petrovic M, Sansil S, Neuger A, Ozakinci H, Boyle TA, Kim J, Haura EB, Gray JE. A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations. Lung Cancer. 2023 Sep.183:107313. Pubmedid: 37499521.
• Gilardone S, Thapa R, Laborde J, Shafique M, Saltos A, Creelan B, Tanvetyanon T, Chiappori A, Simon G, Haura EB, Gray JE, Chen DT, Melzer D, Pellini B. Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation. J Thorac Dis. 2023 Nov.15(11):6115-6125. Pubmedid: 38090314. Pmcid: PMC10713299.
• Liveringhouse CL, Latifi K, Asous AG, Lam NB, Rosenberg SA, Dilling TJ, MacMillan GV, Chiappori AA, Haura EB, Creelan B, Gray JE, Tanvetyanon T, Shafique MR, Saltos AN, Weiner AA, Clarke J, Kelsey CR, Kim S, Caudell JJ, Rose TA, Conejo-Garcia JR, Li J, Schell MJ, Antonia SJ, Perez BA. Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2023 Jul.116(4):837-848. Pubmedid: 36657497.
• Puri S, Saltos AN, Gray JE. Race-inclusive and equitable access to immune checkpoint inhibitor therapy: What are the biggest hurdles?. Cancer. 2023 Dec.129(23):3692-3693. Pubmedid: 37728029.
• Dudek AZ, Xi MX, Scilla KA, Mamdani H, Creelan BC, Saltos A, Tanvetyanon T, Chiappori A. Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299. JTO Clin Res Rep. 2023 Dec.4(12):100584. Pubmedid: 38046376. Pmcid: PMC10689266.
• Zheng H, Yu X, Ibrahim ML, Foresman D, Xie M, Johnson JO, Boyle TA, Ruffell B, Perez BA, Antonia SJ, Ready N, Saltos AN, Cantwell MJ, Beg AA. Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity. Cancer Immunol Res. 2023 Apr.11(4):466-485. Pubmedid: 36757308. Pmcid: PMC10165690.
• Chen DT, Saltos AN, Rose T, Thompson ZJ, Thapa R, Chiappori A, Gray JE. Early Adverse Event Derived Biomarkers in Predicting Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy. Cancers (Basel). 2023 Apr.15(9). Pubmedid: 37173987. Pmcid: PMC10177532.
• Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan.386(3):241-251. Pubmedid: 34534430. Pmcid: PMC9066448.
• Turner K, Brownstein NC, Thompson Z, El Naqa I, Luo Y, Jim HSL, Rollison DE, Howard R, Zeng D, Rosenberg SA, Perez B, Saltos A, Oswald LB, Gonzalez BD, Islam JY, Alishahi Tabriz A, Zhang W, Dilling TJ. Longitudinal patient-reported outcomes and survival among early-stage non-small cell lung cancer patients receiving stereotactic body radiotherapy. Radiother Oncol. 2022 Feb.167:116-121. Pubmedid: 34953934. Pmcid: PMC8934278.
• Chen DT, Chan W, Thompson ZJ, Thapa R, Beg AA, Saltos AN, Chiappori AA, Gray JE, Haura EB, Rose TA, Creelan B. Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer. PLoS One. 2021 Jul.16(7):e0252041. Pubmedid: 34197475. Pmcid: PMC8248740.
• Perez BA, Kim S, Wang M, Karimi AM, Powell C, Li J, Dilling TJ, Chiappori A, Latifi K, Rose T, Lannon A, MacMillan G, Saller J, Grass GD, Rosenberg S, Gray J, Haura E, Creelan B, Tanvetyanon T, Saltos A, Shafique M, Boyle TA, Schell MJ, Conejo-Garcia JR, Antonia SJ. Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2021 Feb.109(2):425-435. Pubmedid: 33002543. Pmcid: PMC8465780.
• Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, Landin AM, Mullinax JE, Saller JJ, Saltos AN, Noyes DR, Montoya LB, Curry W, Pilon-Thomas SA, Chiappori AA, Tanvetyanon T, Kaye FJ, Thompson ZJ, Yoder SJ, Fang B, Koomen JM, Sarnaik AA, Chen DT, Conejo-Garcia JR, Haura EB, Antonia SJ. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med. 2021 Aug.27(8):1410-1418. Pubmedid: 34385708. Pmcid: PMC8509078.
• Puri S, Saltos A, Perez B, Le X, Gray JE. Locally Advanced, Unresectable Non-Small Cell Lung Cancer. Curr Oncol Rep. 2020 Mar.22(4):31. Pubmedid: 32140986.
• Saltos A, Antonia S. Breaking the Impasse: Advances in Treatment of Small Cell Lung Cancer. Clin Chest Med. 2020 Jun.41(2):269-280. Pubmedid: 32402362.
• Saltos A, Shafique M, Chiappori A. Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC). Front Oncol. 2020 Jul.10:1074. Pubmedid: 32766139. Pmcid: PMC7378389.
• Gray JE, Saltos AN, Tanvetyanon T, Haura EB, Creelan BC, Antonia SJ, Shafique M, Zheng H, Dai W, Saller JJ, Chen Z, Tchekmedyian N, Goas K, Thapa R, Boyle TA, Chen DT, Beg AA. Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer. Clin Cancer Res. 2019 Nov.25(22):6623-6632. Pubmedid: 31409616. Pmcid: PMC7234799.
• Saltos A, Khalil F, Smith M, Li J, Schell M, Antonia SJ, Gray JE. Clinical associations of mucin 1 in human lung cancer and precancerous lesions. Oncotarget. 2018 Nov.9(86):35666-35675. Pubmedid: 30479696. Pmcid: PMC6235019.
• Dagogo-Jack I, Saltos A, Shaw AT, Gray JE. Pathology Issues in Thoracic Oncology: Histologic Characterization and Tissue/Plasma Genotyping May Resolve Diagnostic Dilemmas. Am Soc Clin Oncol Educ Book. 2017 Nov.37:619-629. Pubmedid: 28561671.
• Pan J, Saltos A, Smith D, Johnson A, Vossoughi J. Comparison of Respiratory Resistance Measurements Made with an Airflow Perturbation Device with Those from Impulse Oscillometry. J Med Eng. 2016 Mar.2013:165782. Pubmedid: 27006908. Pmcid: PMC4782682.
• Simard JM, Koltz MT, Polifka AJ, Saltos A, Slawson RG, Kwok Y, Aldrich EF. Spetzler-Martin grade III arteriovenous malformations. Author reply. J Neurosurg. 2013 Sep.119(3):821-822. Pubmedid: 24137780.
• Koltz MT, Polifka AJ, Saltos A, Slawson RG, Kwok Y, Aldrich EF, Simard JM. Long-term outcome of Gamma Knife stereotactic radiosurgery for arteriovenous malformations graded by the Spetzler-Martin classification. J Neurosurg. 2013 Jan.118(1):74-83. Pubmedid: 23082882.
• Smith DC, Schreiber KM, Saltos A, Lichenstein SB, Lichenstein R. Ambulatory cell phone injuries in the United States: an emerging national concern. J Safety Res. 2013 Dec.47:19-23. Pubmedid: 24237866.